JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Odonate Therapeutics Inc

Închisă

0

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

Indicatori cheie

By Trading Economics

Odonate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 23:53 UTC

Câștiguri

Naver Posts Weaker First-Quarter Earnings

29 apr. 2026, 23:41 UTC

Acțiuni populare

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr. 2026, 23:55 UTC

Câștiguri

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr. 2026, 23:54 UTC

Câștiguri

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr. 2026, 23:52 UTC

Câștiguri

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr. 2026, 23:51 UTC

Câștiguri

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss Narrows>000002.SZ

29 apr. 2026, 23:18 UTC

Câștiguri

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr. 2026, 23:17 UTC

Câștiguri

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr. 2026, 23:13 UTC

Câștiguri

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr. 2026, 23:12 UTC

Câștiguri

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr. 2026, 23:04 UTC

Câștiguri

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr. 2026, 23:04 UTC

Câștiguri

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparație

Modificare preț

Odonate Therapeutics Inc Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

$

Despre Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat